K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 acquired 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee for KRW 2.1 billion.
August 02, 2016 at 12:00 am
Share
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 acquired 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee for KRW 2.1 billion on July 28, 2016. As part of the transaction, Kwanghyun Lee acquired 0.09 million shares of Biocore from K2 Asset Securitization Specialty Investment Fund; Seunghyun Lee acquired 0.05 million shares of Biocore from Korea Omega Venture Investment No.1 Fund; Seunghyun Lee acquired 0.03 million shares of Biocore from MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 each for KRW 11,677 per share. In related transactions, Kiwoom Securities Co., Ltd. (KOSE:A039490) acquired 0.27% stake in Biocore Co., Ltd. from Kyungryul Lee for KRW 13,000 per share and Kiwoom Securities Co., Ltd. acquired a minority stake in Biocore from SCL healthcare Co., Ltd. for KRW 13,000 per share.
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 completed the acquisition of 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee on July 28, 2016.
Invites Biocore Co Ltd, formerly BioCore Co Ltd, is a Korea-based company mainly engaged in the provision of medical examination services. The Company operates its business through two segments. The New Drug Development Business segment is involved in the provision of bioequivalence testing, drug in vivo kinetics research, drug analysis in biological samples, toxicity kinetics testing, microanalysis in pharmaceuticals, comparative dissolution testing, and clinical trial consulting. The Biotechnology Business segment is engaged in the provision of customized genome analysis services and the manufacture and sale of diagnostic kits. The Companyâs products are sold under the brand of Bio-Core.
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 acquired 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee for KRW 2.1 billion.
INVITES BIOCORE CO., LTD. 